The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019
| Year | 2019 |
2019 No. 775
Exiting The European Union
Medicines
The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019
Made 1st April 2019
Coming into force in accordance with regulation 1
The Secretary of State makes these Regulations in exercise of the powers conferred by section 8(1) of, and paragraphs 1(1) and 7(2) of Schedule 4 and paragraph 21 of Schedule 7 to, the European Union (Withdrawal) Act 20181.
The Treasury has consented to the making of these Regulations as required by paragraphs 3(1) and 10 of Schedule 4 to the European Union (Withdrawal) Act 2018.
In accordance with paragraphs 1(1) and 12(1) of Schedule 7 to the European Union (Withdrawal) Act 2018, a draft of these Regulations has been laid before and approved by a resolution of each House of Parliament.
PART 1
General
Citation and commencement
1. These Regulations may be cited as the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 and come into force on exit day.
Amendment of the Human Medicines Regulations 2012
2. The Human Medicines Regulations 20122are amended in accordance with Parts 2 to 19.
Amendment of the Medicines (Products for Human Use) (Fees) Regulations 2016
3. Schedule 1 amends the Medicines (Products for Human Use) (Fees) Regulations 20163and makes saving provision.
PART 2
Amendment of Part 1 (General)
Definitions in relation to advanced therapy medicinal products
4. After regulation 2, insert—
“Definition of advanced therapy medicinal product etc.
2A.—(1) In these Regulations, “advanced therapy medicinal product” means any of the following products—
(a)
(a) a gene therapy medicinal product;
(b)
(b) a somatic cell therapy medicinal product; or
(c)
(c) a tissue engineered product.
(2) A “gene therapy medicinal product” is a biological medicinal product which has the following characteristics—
(a)
(a) it contains an active substance which contains or consists of a recombinant nucleic acid used in or administered to human beings with a view to regulating, repairing, replacing, adding or deleting a genetic sequence; and
(b)
(b) its therapeutic, prophylactic or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains, or to the product of genetic expression of this sequence.
(3) A vaccine against infectious diseases is not to be treated as a gene therapy medicinal product.
(4) A “somatic cell medicinal product” is a medicinal product which has the following characteristics—
(a)
(a) it contains or consists of cells or tissues that—
(i) have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered, or
(ii) are not intended to be used for the same essential function in the recipient as in the donor; and
(b)
(b) it is presented as having properties for, or is used in or administered to human beings with a view to, treating, preventing or diagnosing a disease through the pharmacological, immunological or metabolic action of its cells or tissues.
(5) A “tissue engineered product” is a medicinal product which—
(a)
(a) contains or consists of engineered cells or tissues; and
(b)
(b) is presented as having properties for, or is used in or administered to human beings with a view to, regenerating, repairing or replacing a human tissue.
(6) A tissue engineered product may contain—
(a)
(a) cells or tissues of human or animal origin;
(b)
(b) viable or non-viable cells or tissues; and
(c)
(c) additional substances, including cellular products, bio-molecules, biomaterials, chemical substances, scaffolds or matrices.
(7) A product is not a tissue engineered product if it—
(a)
(a) contains or consists exclusively of non-viable human or animal cells or tissues;
(b)
(b) does not contain any viable cells or tissues; and
(c)
(c) does not act principally by pharmacological, immunological or metabolic action.
(8) Cells or tissues are engineered if they—
(a)
(a) have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved; or
(b)
(b) are not intended to be used for the same essential function in the recipient as in the donor.
(9) The following manipulations are not substantial manipulations for the purposes of paragraphs (4)(a) and (8)(a)—
(a)
(a) cutting;
(b)
(b) grinding;
(c)
(c) shaping;
(d)
(d) centrifugation;
(e)
(e) soaking in antibiotic or antimicrobial solutions;
(f)
(f) sterilisation;
(g)
(g) irradiation;
(h)
(h) cell separation, concentration or purification;
(i)
(i) filtering;
(j)
(j) lyophilisation;
(k)
(k) freezing;
(l)
(l) cryopreservation; and
(m)
(m) vitrification.
(10) In these Regulations, “combined advanced therapy medicinal product” means an advanced therapy medicinal product—
(a)
(a) which incorporates, as an integral part of the product, one or more medical devices or one or more active implantable medical devices; and
(b)
(b) the cellular part of which—
(i) contains viable cells or tissues; or
(ii) contains non-viable cells or tissues which are liable to act upon the human body with action that can be considered as primary to that of the medical devices.
(11) Where an advanced therapy medicinal product contains viable cells or tissues, the pharmacological, immunological or metabolic action of those cells or tissues is to be treated as the principal mode of action of the product.
(12) An advanced therapy medicinal product containing both autologous and allogeneic cells or tissues is to be treated as being for allogeneic use.
(13) A product which falls within the definition of a tissue engineered product and within the definition of a somatic cell therapy medicinal product is to be treated as a tissue engineered product.
(14) A product which falls within the definition of—
(a)
(a) a somatic cell therapy medicinal product or a tissue engineered product; and
(b)
(b) a gene therapy medicinal product,
is to be treated as a gene therapy medicinal product.”.
Amendment of regulation 3 (scope of Regulations: special provisions)
5.—(1) Regulation 3 is amended as follows.
(2) In paragraph (12)(d)—
(a)
(a) in paragraph (i) insert “UK” before “marketing authorisation”;
(b)
(b) at the end of paragraph (ii) insert “or”; and
(c)
(c) omit paragraph (iv) (and “or” immediately preceding it).
(3) In paragraph (15)—
(a)
(a) in sub-paragraph (a) insert “UK” before “marketing authorisation”; and
(b)
(b) at the end of sub-paragraph (b) insert “or”; and
(c)
(c) omit sub-paragraph (d) (and “or” immediately preceding it).
Amendment of regulation 4 (special provision for pharmacies etc)
6. In regulation 4(4)(d)—
(a) in paragraph (i) insert “UK” before “marketing authorisation”;
(b) at the end of paragraph (ii) insert “or”; and
(c) omit paragraph (iv) (and “or” immediately preceding it).
Amendment of regulation 5 (classification of medicinal products)
7.—(1) Regulation 5 is amended as follows.
(2) Omit paragraph (1)(b) (and “or” immediately preceding it).
(3) In paragraph (2)—
(a)
(a) at the end of sub-paragraph (b), insert “or”; and
(b)
(b) omit sub-paragraph (d) (and “or” immediately preceding it).
(4) In paragraph (3)—
(a)
(a) omit sub-paragraph (b); and
(b)
(b) in paragraph (d), omit “or (b)”.
(5) In paragraph (4), omit sub-paragraph (b) (and “or” immediately preceding it).
(6) In paragraph (5)—
(a)
(a) omit sub-paragraph (b); and
(b)
(b) in paragraph (d), omit “or (b)”.
Amendment of Schedule 1 (further provisions for classification of medicinal products)
8. In Schedule 14, in each place where it occurs, insert “UK” before “marketing authorisation”.
Amendment of regulation 6 (the licensing authority and the Ministers)
9. In regulation 6—
(a) in paragraph (3) omit sub-paragraph (b) (and “or” immediately preceding it); and
(b) omit paragraphs (4) and (5).
Amendment of regulation 8 (general interpretation)
10.—(1) Regulation 85is amended as follows.
(2) In paragraph (1), at the appropriate places, insert—
““active implantable medical device”—
(a) has the meaning given in regulation 2 of the Medical Devices Regulations 20026; or
(b) to the extent necessary for the practical application of that definition, also or instead has the meaning given in regulation 137 of those Regulations7;”;
““agreed paediatric investigation plan” means a paediatric investigation plan which the licensing authority has agreed in accordance with regulation 50B;”;
““Annex I to the 2001 Directive” means Annex I to the 2001 Directive, as modified in accordance with Schedule 8B;”;
““approved country for batch testing list” means the list published by the licensing authority under paragraph 14(3) of Schedule 7 (obligations of qualified persons) and “approved country for batch testing” means a country included in that list;”;
““approved country for import list” means the list published by the licensing authority under regulation 18A (approved country for import) and “approved country for import” means a country included in that list;”;
““the Committee for Medicinal Products for Human Use” means the committee established under Article 5(1) of Regulation (EC) No 726/2004;”;
““conditional marketing authorisation” means a UK marketing authorisation granted under regulation 49(1)(a) in accordance with regulation...
To continue reading
Request your trial